
Moderna Inc. announced Wednesday that it has seen positive early results with a new vaccine that would guard against four strains of flu plus COVID-19. In interim findings from a Phase 1/2 trial, the vaccine showed both a strong immune response compared to the standard dose of flu vaccine in adults aged 50 to 64… read on > read on >